Marinomed Biotech AG (MARI) NPV
Marinomed Biotechnologie GmbH is an Austria-based biopharmaceutical company engaged in the pharmaceuticals industry. The Company develops anti-viral and immunological therapies, such as nasal sprays, using the antiviral respiratory technology platform MAVIREX, which target more than 200 different respiratory virus strains based on Carragelose, a red algae derived polymer. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. In addition, the Company develops treatments against type I allergy and autoimmune diseases. The Company operates as a spin-off from the Veterinary University of Vienna.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.